sorafenib has been researched along with 22,23-dihydroavermectin b(1)a in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (22,23-dihydroavermectin b(1)a) | Trials (22,23-dihydroavermectin b(1)a) | Recent Studies (post-2010) (22,23-dihydroavermectin b(1)a) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 21 | 1 | 14 |
| Protein | Taxonomy | sorafenib (IC50) | 22,23-dihydroavermectin b(1)a (IC50) |
|---|---|---|---|
| 60 kDa chaperonin | Escherichia coli | 9.5 | |
| 10 kDa chaperonin | Escherichia coli | 9.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laufer, S; Pillaiyar, T | 1 |
1 review(s) available for sorafenib and 22,23-dihydroavermectin b(1)a
| Article | Year |
|---|---|
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |